Chemotherapy has been the standard treatment for urothelial bladder cancer that has spread and grown beyond the urinary tract. For some patients, standard “platinum-based” chemotherapy drugs (such as cisplatin) are not safe to give due to their side effects, and in many patients who have already received these drugs, the cancer later comes back.
In this study, researchers are evaluating the safety and effectiveness of an investigational drug called MPDL3280A in patients with locally advanced or metastatic urothelial cancer who cannot be treated with cisplatin or whose cancer has returned after platinum-based treatment. Two groups of patients will be eligible for this study:
- Patients who have never received platinum-based chemotherapy for urothelial cancer who are either unable to receive cisplatin or who have relapsed more than 12 months after receiving pre- or post-operative chemotherapy.
- Patients whose cancer has grown or spread after receiving at least two cycles of platinum-based chemotherapy, either for metastatic cancer or for relapse within 12 months after pre- or post-operative chemotherapy.
MPDL3280A is designed to improve the immune system’s ability to recognize and destroy cancer cells by blocking PD-L1, a protein made by some cancers. It is given intravenously (by vein).